PubMed:10318905 / 398-715 JSONTXT

{"project":"PMID_GLOBAL","denotations":[{"id":"T7","span":{"begin":50,"end":53},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":83,"end":86},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":245,"end":260},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T10","span":{"begin":274,"end":277},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A7","pred":"mondo_id","subj":"T7","obj":"0012041"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"0012041"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"0008315"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"0012041"}],"text":"Using AG879, a HER2/Neu inhibitor, and PD98059, a MAP kinase inhibitor, as well as MAP kinase phosphatase-1 (MPK-1), in the transfection assay, we found that HER2/Neu could induce prostate-specific antigen (PSA), a marker for the progression of prostate cancer, through the MAP kinase pathway at a low androgen level."}

{"project":"sentences","denotations":[{"id":"TextSentencer_T4","span":{"begin":0,"end":317},"obj":"Sentence"},{"id":"T4","span":{"begin":0,"end":317},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Using AG879, a HER2/Neu inhibitor, and PD98059, a MAP kinase inhibitor, as well as MAP kinase phosphatase-1 (MPK-1), in the transfection assay, we found that HER2/Neu could induce prostate-specific antigen (PSA), a marker for the progression of prostate cancer, through the MAP kinase pathway at a low androgen level."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"10318905-3#109#114#gene1843","span":{"begin":109,"end":114},"obj":"gene1843"},{"id":"10318905-3#245#260#diseaseC0376358","span":{"begin":245,"end":260},"obj":"diseaseC0376358"},{"id":"10318905-3#245#260#diseaseC0600139","span":{"begin":245,"end":260},"obj":"diseaseC0600139"}],"relations":[{"id":"109#114#gene1843245#260#diseaseC0376358","pred":"associated_with","subj":"10318905-3#109#114#gene1843","obj":"10318905-3#245#260#diseaseC0376358"},{"id":"109#114#gene1843245#260#diseaseC0600139","pred":"associated_with","subj":"10318905-3#109#114#gene1843","obj":"10318905-3#245#260#diseaseC0600139"}],"text":"Using AG879, a HER2/Neu inhibitor, and PD98059, a MAP kinase inhibitor, as well as MAP kinase phosphatase-1 (MPK-1), in the transfection assay, we found that HER2/Neu could induce prostate-specific antigen (PSA), a marker for the progression of prostate cancer, through the MAP kinase pathway at a low androgen level."}

{"project":"DisGeNet-2017-sample","denotations":[{"id":"T610","span":{"begin":109,"end":114},"obj":"gene:1843"},{"id":"T611","span":{"begin":245,"end":260},"obj":"disease:C0376358"}],"relations":[{"id":"R9","pred":"associated_with","subj":"T610","obj":"T611"},{"id":"R10","pred":"associated_with","subj":"T610","obj":"T611"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Using AG879, a HER2/Neu inhibitor, and PD98059, a MAP kinase inhibitor, as well as MAP kinase phosphatase-1 (MPK-1), in the transfection assay, we found that HER2/Neu could induce prostate-specific antigen (PSA), a marker for the progression of prostate cancer, through the MAP kinase pathway at a low androgen level."}

{"project":"DisGeNET","denotations":[{"id":"T12","span":{"begin":109,"end":114},"obj":"gene:1843"},{"id":"T13","span":{"begin":245,"end":260},"obj":"disease:C0600139"},{"id":"T14","span":{"begin":207,"end":210},"obj":"gene:354"},{"id":"T15","span":{"begin":245,"end":260},"obj":"disease:C0600139"},{"id":"T16","span":{"begin":109,"end":114},"obj":"gene:1843"},{"id":"T17","span":{"begin":245,"end":260},"obj":"disease:C0376358"},{"id":"T18","span":{"begin":207,"end":210},"obj":"gene:354"},{"id":"T19","span":{"begin":245,"end":260},"obj":"disease:C0376358"}],"relations":[{"id":"R7","pred":"associated_with","subj":"T12","obj":"T13"},{"id":"R8","pred":"associated_with","subj":"T14","obj":"T15"},{"id":"R9","pred":"associated_with","subj":"T16","obj":"T17"},{"id":"R10","pred":"associated_with","subj":"T18","obj":"T19"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Using AG879, a HER2/Neu inhibitor, and PD98059, a MAP kinase inhibitor, as well as MAP kinase phosphatase-1 (MPK-1), in the transfection assay, we found that HER2/Neu could induce prostate-specific antigen (PSA), a marker for the progression of prostate cancer, through the MAP kinase pathway at a low androgen level."}

{"project":"PubmedHPO","denotations":[{"id":"T6","span":{"begin":245,"end":260},"obj":"HP_0012125"},{"id":"T7","span":{"begin":254,"end":260},"obj":"HP_0002664"}],"text":"Using AG879, a HER2/Neu inhibitor, and PD98059, a MAP kinase inhibitor, as well as MAP kinase phosphatase-1 (MPK-1), in the transfection assay, we found that HER2/Neu could induce prostate-specific antigen (PSA), a marker for the progression of prostate cancer, through the MAP kinase pathway at a low androgen level."}